This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


1aid

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
A stable, non-peptide inhibitor of the protease from type 1 human, immunodeficiency virus has been developed, and the stereochemistry of, binding defined through crystallographic three-dimensional structure, determination. The initial compound, haloperidol, was discovered through, computational screening of the Cambridge Structural Database using a shape, complementarity algorithm. The subsequent modification is a non-peptidic, lateral lead, which belongs to a family of compounds with well, characterized pharmacological properties. This thioketal derivative of, haloperidol and a halide counterion are bound within the enzyme active, site in a mode distinct from the observed for peptide-based inhibitors. A, variant of the protease cocrystallized with this inhibitor shows binding, in the manner predicted during the initial computer-based search. The, structures provide the context for subsequent synthetic modifications of, the inhibitor.
+
A stable, non-peptide inhibitor of the protease from type 1 human immunodeficiency virus has been developed, and the stereochemistry of binding defined through crystallographic three-dimensional structure determination. The initial compound, haloperidol, was discovered through computational screening of the Cambridge Structural Database using a shape complementarity algorithm. The subsequent modification is a non-peptidic lateral lead, which belongs to a family of compounds with well characterized pharmacological properties. This thioketal derivative of haloperidol and a halide counterion are bound within the enzyme active site in a mode distinct from the observed for peptide-based inhibitors. A variant of the protease cocrystallized with this inhibitor shows binding in the manner predicted during the initial computer-based search. The structures provide the context for subsequent synthetic modifications of the inhibitor.
==About this Structure==
==About this Structure==
Line 14: Line 14:
[[Category: Human immunodeficiency virus]]
[[Category: Human immunodeficiency virus]]
[[Category: Single protein]]
[[Category: Single protein]]
-
[[Category: Fauman, E.B.]]
+
[[Category: Fauman, E B.]]
-
[[Category: Keenan, R.J.]]
+
[[Category: Keenan, R J.]]
-
[[Category: Rutenber, E.E.]]
+
[[Category: Rutenber, E E.]]
-
[[Category: Stroud, R.M.]]
+
[[Category: Stroud, R M.]]
[[Category: CL]]
[[Category: CL]]
[[Category: THK]]
[[Category: THK]]
Line 26: Line 26:
[[Category: protease]]
[[Category: protease]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 15:28:58 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 11:44:54 2008''

Revision as of 09:44, 21 February 2008


1aid, resolution 2.2Å

Drag the structure with the mouse to rotate

STRUCTURE OF A NON-PEPTIDE INHIBITOR COMPLEXED WITH HIV-1 PROTEASE: DEVELOPING A CYCLE OF STRUCTURE-BASED DRUG DESIGN

Overview

A stable, non-peptide inhibitor of the protease from type 1 human immunodeficiency virus has been developed, and the stereochemistry of binding defined through crystallographic three-dimensional structure determination. The initial compound, haloperidol, was discovered through computational screening of the Cambridge Structural Database using a shape complementarity algorithm. The subsequent modification is a non-peptidic lateral lead, which belongs to a family of compounds with well characterized pharmacological properties. This thioketal derivative of haloperidol and a halide counterion are bound within the enzyme active site in a mode distinct from the observed for peptide-based inhibitors. A variant of the protease cocrystallized with this inhibitor shows binding in the manner predicted during the initial computer-based search. The structures provide the context for subsequent synthetic modifications of the inhibitor.

About this Structure

1AID is a Single protein structure of sequence from Human immunodeficiency virus with and as ligands. Active as HIV-1 retropepsin, with EC number 3.4.23.16 Full crystallographic information is available from OCA.

Reference

Structure of a non-peptide inhibitor complexed with HIV-1 protease. Developing a cycle of structure-based drug design., Rutenber E, Fauman EB, Keenan RJ, Fong S, Furth PS, Ortiz de Montellano PR, Meng E, Kuntz ID, DeCamp DL, Salto R, et al., J Biol Chem. 1993 Jul 25;268(21):15343-6. PMID:8340363

Page seeded by OCA on Thu Feb 21 11:44:54 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools